Identification

Name
Triprolidine
Accession Number
DB00427  (APRD00306)
Type
Small Molecule
Groups
Approved
Description

First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

Structure
Thumb
Synonyms
  • Tripolidina
  • Triprolidin
  • Triprolidine
  • Triprolidinum
Product Ingredients
IngredientUNIICASInChI Key
Triprolidine hydrochlorideNG7A104R3J550-70-9WYUYEJNGHIOFOC-NWBUNABESA-N
Triprolidine hydrochloride monohydrateYAN7R5L8906138-79-0CUZMOIXUFHOLLN-UMVVUDSKSA-N
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HistexSyrup2.5 mg/5mLOralAllegis Pharmaceuticals, LLC2014-03-04Not applicableUs
HistexTablet, chewable1.25 mg/1OralAllegis Pharmaceuticals, LLC2017-07-24Not applicableUs
HISTEX PD DropsSyrup.938 mg/mLOralAllegis Pharmaceuticals, LLC2014-03-06Not applicableUs
HISTEX PDX DropsSyrup1.25 mg/mLOralAllegis Pharmaceuticals, LLC2017-06-22Not applicableUs
M-Hist PDLiquid.625 mg/mLOralMethod Pharmaceuticals2016-11-08Not applicableUs
Triprolidine HydrochlorideLiquid.625 mg/mLOralWoodward Pharma Services Llc2016-10-10Not applicableUs
VanaClear PDLiquid.313 mg/mLOralGm Pharmaceuticals2016-04-04Not applicableUs
Vanahist PdLiquid.625 mg/mLOralGm Pharmaceuticals2014-03-19Not applicableUs
International/Other Brands
Anmin (AND) / Venen (Sato Seiyaku)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Actifed DM SyrupTriprolidine hydrochloride (1.25 mg) + Dextromethorphan hydrobromide (15 mg) + Pseudoephedrine hydrochloride (30 mg)SyrupOralGlaxo Wellcome1980-12-312000-08-03Canada
Actifed DM SyrupTriprolidine hydrochloride (1.25 mg) + Dextromethorphan hydrobromide (15 mg) + Pseudoephedrine hydrochloride (30 mg)SyrupOralWarner Lambert Canada Inc.Not applicableNot applicableCanada
Actifed DM TabletsTriprolidine hydrochloride (2.5 mg) + Dextromethorphan hydrobromide (30 mg) + Pseudoephedrine hydrochloride (60 mg)TabletOralWarner Lambert Canada Inc.Not applicableNot applicableCanada
Actifed DM TabletsTriprolidine hydrochloride (2.5 mg) + Dextromethorphan hydrobromide (30 mg) + Pseudoephedrine hydrochloride (60 mg)TabletOralGlaxo Wellcome1994-12-312000-08-03Canada
Actifed Plus CapletTriprolidine hydrochloride (2.5 mg) + Acetaminophen (500 mg) + Pseudoephedrine hydrochloride (60 mg)TabletOralGlaxo Wellcome1991-12-312000-08-03Canada
Actifed Plus CapletsTriprolidine hydrochloride (2.5 mg) + Acetaminophen (500 mg) + Pseudoephedrine hydrochloride (60 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc2000-04-142016-01-22Canada
Actifed SyrupTriprolidine hydrochloride (1.25 mg) + Pseudoephedrine hydrochloride (30 mg)LiquidOralGlaxo Wellcome1960-12-312000-08-03Canada
Actifed TabletsTriprolidine hydrochloride (2.5 mg) + Pseudoephedrine hydrochloride (60 mg)TabletOralGlaxo Wellcome1960-12-312000-08-03Canada
Actifed TabletsTriprolidine hydrochloride (2.5 mg) + Pseudoephedrine hydrochloride (60 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1999-12-222016-01-22Canada
AprodineTriprolidine hydrochloride (2.5 mg/1) + Pseudoephedrine hydrochloride (60 mg/1)Tablet, film coatedOralA S Medication Solutions1993-01-09Not applicableUs
Categories
UNII
2L8T9S52QM
CAS number
486-12-4
Weight
Average: 278.3914
Monoisotopic: 278.178298714
Chemical Formula
C19H22N2
InChI Key
CBEQULMOCCWAQT-WOJGMQOQSA-N
InChI
InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
IUPAC Name
2-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridine
SMILES
CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1

Pharmacology

Indication

For the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis; allergic conjunctivitis; and mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold.

Structured Indications
Pharmacodynamics

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Triprolidine, is a histamine H1 antagonist that competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Triprolidine has anticholinergic and sedative effects.

Mechanism of action

Triprolidine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Rapidly absorbed in the intestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

4 to 6 hours.

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, weakness, inco-ordination, difficulty with micturition, respiratory depression, hypotension, agitation, irritability, convulsions, hypertension, palpitation and tachycardia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Triprolidine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Triprolidine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Triprolidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Triprolidine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Triprolidine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Triprolidine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Triprolidine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Triprolidine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Triprolidine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Triprolidine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triprolidine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Triprolidine.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Triprolidine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Triprolidine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triprolidine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Triprolidine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Triprolidine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Triprolidine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Triprolidine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Triprolidine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triprolidine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Triprolidine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Triprolidine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Triprolidine.Investigational, Vet Approved
AzelastineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Triprolidine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Triprolidine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Triprolidine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Triprolidine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Triprolidine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Triprolidine.Approved
Benzylpenicilloyl PolylysineTriprolidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Triprolidine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Triprolidine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Triprolidine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Triprolidine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Triprolidine.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triprolidine.Approved, Investigational
BuprenorphineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Triprolidine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triprolidine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Triprolidine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Triprolidine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Triprolidine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Triprolidine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triprolidine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Triprolidine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triprolidine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Triprolidine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Triprolidine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Triprolidine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Triprolidine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triprolidine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Triprolidine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Triprolidine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Triprolidine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triprolidine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Triprolidine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Triprolidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Triprolidine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Triprolidine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Triprolidine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Triprolidine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Triprolidine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Triprolidine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triprolidine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Triprolidine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triprolidine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Triprolidine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triprolidine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triprolidine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triprolidine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Triprolidine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Triprolidine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Triprolidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triprolidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Triprolidine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triprolidine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triprolidine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Triprolidine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Triprolidine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Triprolidine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Triprolidine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triprolidine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triprolidine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triprolidine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triprolidine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triprolidine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Triprolidine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Triprolidine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Triprolidine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Triprolidine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triprolidine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Triprolidine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Triprolidine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Triprolidine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Triprolidine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Triprolidine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Triprolidine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Triprolidine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triprolidine.Approved
EthanolTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triprolidine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Triprolidine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Triprolidine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Triprolidine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triprolidine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Triprolidine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Triprolidine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Triprolidine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Triprolidine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triprolidine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Triprolidine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triprolidine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Triprolidine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Triprolidine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Triprolidine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Triprolidine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triprolidine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triprolidine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triprolidine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Triprolidine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Triprolidine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Triprolidine.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triprolidine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Triprolidine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Triprolidine.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Triprolidine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Triprolidine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Triprolidine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Triprolidine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triprolidine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Triprolidine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Triprolidine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Triprolidine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triprolidine.Approved, Investigational
HydrocodoneTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triprolidine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Triprolidine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Triprolidine.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Triprolidine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Triprolidine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Triprolidine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Triprolidine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triprolidine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Triprolidine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triprolidine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triprolidine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triprolidine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Triprolidine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Triprolidine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Triprolidine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Triprolidine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triprolidine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Triprolidine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triprolidine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Triprolidine.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Triprolidine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Triprolidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Triprolidine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Triprolidine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Triprolidine.Investigational
MephentermineMephentermine may decrease the sedative activities of Triprolidine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Triprolidine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triprolidine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Triprolidine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Triprolidine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triprolidine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Triprolidine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Triprolidine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Triprolidine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Triprolidine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Triprolidine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Triprolidine.Approved
MethotrimeprazineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Triprolidine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Triprolidine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Triprolidine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Triprolidine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Triprolidine.Approved, Investigational
MetyrosineTriprolidine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triprolidine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Triprolidine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Triprolidine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved, Investigational
MirtazapineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Triprolidine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Triprolidine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triprolidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triprolidine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Triprolidine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Triprolidine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Triprolidine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Triprolidine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triprolidine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Triprolidine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Triprolidine.Approved, Illicit
OrphenadrineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Triprolidine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triprolidine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Triprolidine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Triprolidine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Triprolidine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triprolidine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triprolidine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Triprolidine.Approved
ParaldehydeTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Triprolidine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triprolidine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triprolidine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Triprolidine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Triprolidine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triprolidine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triprolidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Triprolidine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Triprolidine.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triprolidine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Triprolidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Triprolidine.Approved
PhenterminePhentermine may decrease the sedative activities of Triprolidine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Triprolidine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Triprolidine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Triprolidine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Triprolidine.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pomalidomide.Approved
PramipexoleTriprolidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Triprolidine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Triprolidine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triprolidine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Triprolidine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Triprolidine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Triprolidine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triprolidine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triprolidine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Triprolidine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Triprolidine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Triprolidine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Triprolidine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triprolidine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Triprolidine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Triprolidine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Triprolidine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Triprolidine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triprolidine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Triprolidine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Triprolidine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triprolidine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triprolidine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triprolidine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Triprolidine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Triprolidine.Investigational
RitobegronRitobegron may decrease the sedative activities of Triprolidine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Triprolidine.Vet Approved
RopiniroleTriprolidine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triprolidine.Approved
RotigotineTriprolidine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Triprolidine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triprolidine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Triprolidine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Triprolidine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Triprolidine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Triprolidine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triprolidine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Triprolidine.Experimental
SuvorexantTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Triprolidine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triprolidine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Triprolidine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Triprolidine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Triprolidine.Investigational
ThalidomideTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Triprolidine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Triprolidine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Triprolidine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Triprolidine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Triprolidine.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Triprolidine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Triprolidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Triprolidine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Triprolidine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triprolidine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Triprolidine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triprolidine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Triprolidine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Triprolidine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Triprolidine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Triprolidine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triprolidine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Triprolidine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triprolidine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trimipramine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Triprolidine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Triprolidine.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Triprolidine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Triprolidine.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Triprolidine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Triprolidine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Triprolidine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Triprolidine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triprolidine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Triprolidine.Vet Approved
ZolpidemTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Triprolidine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Triprolidine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triprolidine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44. [PubMed:2568212]
  2. Simons FE: H1-receptor antagonists. Comparative tolerability and safety. Drug Saf. 1994 May;10(5):350-80. [PubMed:7913608]
  3. Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055]
  4. Telekes A, Holland RL, Withington DA, Peck AW: Effects of triprolidine and dipipanone in the cold induced pain test, and the central nervous system of healthy volunteers. Br J Clin Pharmacol. 1987 Jul;24(1):43-50. [PubMed:3620284]
External Links
Human Metabolome Database
HMDB14571
KEGG Drug
D01782
PubChem Compound
5282443
PubChem Substance
46505403
ChemSpider
4445597
BindingDB
50292411
ChEBI
84116
ChEMBL
CHEMBL855
Therapeutic Targets Database
DAP001065
PharmGKB
PA451797
IUPHAR
1228
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Triprolidine
ATC Codes
R06AX07 — Triprolidine
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Usl pharma inc
  • Alpharma us pharmaceuticals division
  • Halsey drug co inc
  • Pharmaceutical assoc inc div beach products
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Tablet, coatedOral
SyrupOral2.5 mg/5mL
Tablet, chewableOral1.25 mg/1
SyrupOral
SyrupOral.938 mg/mL
SyrupOral1.25 mg/mL
LiquidOral
LiquidOral.313 mg/mL
LiquidOral.625 mg/mL
Prices
Unit descriptionCostUnit
Triprolidine hcl crystals40.33USD g
Triprolidine 1.25 mg/5 ml liq0.15USD ml
Tripohist 1.25 mg/5 ml liquid0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)60 °CPhysProp
water solubility74.9 mg/LNot Available
logP3.92HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0537 mg/mLALOGPS
logP4.14ALOGPS
logP4.05ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)8.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.53 m3·mol-1ChemAxon
Polarizability33.09 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9905
Blood Brain Barrier+0.9664
Caco-2 permeable-0.5814
P-glycoprotein substrateSubstrate0.6644
P-glycoprotein inhibitor IInhibitor0.8311
P-glycoprotein inhibitor IINon-inhibitor0.6624
Renal organic cation transporterInhibitor0.8612
CYP450 2C9 substrateNon-substrate0.8143
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6075
CYP450 1A2 substrateNon-inhibitor0.8613
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8598
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9551
BiodegradationNot ready biodegradable0.9833
Rat acute toxicity2.7123 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7001
hERG inhibition (predictor II)Non-inhibitor0.5557
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-2690000000-a4b47440bb135b0a9add
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Styrenes
Direct Parent
Styrenes
Alternative Parents
Toluenes / Pyridines and derivatives / N-alkylpyrrolidines / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Styrene / Toluene / Pyridine / N-alkylpyrrolidine / Pyrrolidine / Heteroaromatic compound / Tertiary aliphatic amine / Tertiary amine / Organoheterocyclic compound / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyridines, olefinic compound, N-alkylpyrrolidine (CHEBI:84116)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Peroutka SJ, Snyder SH: Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain. Brain Res. 1981 Mar 16;208(2):339-47. [PubMed:7214150]
  2. Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96. [PubMed:3011460]
  3. Kuzmin AI, Zaretsky DV, Kalenikova EI, Zaretskaja MV, Medvedev OS, Chazov EI: The effect of histamine receptor antagonists on stress-induced catecholamine secretion: an adrenomedullary microdialysis study in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):311-6. [PubMed:10493107]
  4. Ziganshina LE, Ziganshin AU, Hoyle CH, Burnstock G: Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved. Inflamm Res. 1996 Feb;45(2):96-102. [PubMed:8907591]
  5. Hiroi T, Ohishi N, Imaoka S, Yabusaki Y, Fukui H, Funae Y: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol Exp Ther. 1995 Feb;272(2):939-44. [PubMed:7853212]
  6. Estelle F, Simons R: H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999 Nov;83(5):481-8. [PubMed:10582735]
  7. Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44. [PubMed:2568212]
  8. Simons FE: H1-receptor antagonists. Comparative tolerability and safety. Drug Saf. 1994 May;10(5):350-80. [PubMed:7913608]
  9. Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055]
  10. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 14:27